|
| | Target | Role in prostate cancer | Prognostic role |
|
| MiR-15/16 [47–49] | BCL2, CCDN1, WNT3A, also fibroblast growth factor-2 in tumor stroma | Downregulated cell survival, proliferation, invasion | Indirect: 13q del progression |
|
| MiR-21 [50–52] | Inhibits PTEN, PDCD4, TPM1, MARCKS | Down regulated invasion and migration | BCR |
|
| MiR-23 [53] | Repressed by MYC | Down regulated mitochondrial activity | |
|
| miR-25 [54] | Cluster with miR-106b, inhibits PTEN | Overexpression tumorigenesis | |
|
| miR-31 [55] | Inhibits radixin | Down regulated invasion | Gleason |
|
| miR-32 [54] | Homologue of miR-25, inhibits Bim, pro-apoptotic gene | Overexpression cell survival | EPE |
|
| miR-34 [56, 57] | Target of p53 | Down regulated P53 mediated apoptosis disrupted. May affect cancer stem cells | |
|
| miR-96 [55] | Inhibits hZIP1 | Overexpression decrease zinc uptake | Gleason |
|
| miR-100 [47, 58] | THAP2 regulates cell cycle, SMARCA5 DNA replication, BAZ2A inhibits DNA replication | | Decreased progression
Increased BCR |
|
| miR-125b [55] | Inhibits BAK1 | Inhibits apoptosis | Stage |
|
| miR-135b [59] | Inhibits mismatch repair gene MSH2 | Overexpression genomic instability | BCR |
|
| miR-145 [60–62] | Inhibits c-MYC | Upregulated or downregulated | Gleason |
|
| miR-194 [59] | Inhibits de novo methyltransferase DNMT3a | Overexpression hypomethylation, genomic instability | BCR |
|
| miR-196a [54] | HoxB8 | Overexpression cell survival | EPE |
|
| miR-205 [55] | Inhibits Laminin 5β3, SIP1, ZEP | Downregulation invasion | Gleason, stage |
|
| miR-221/222 [55] | Inhibit p27, p57, PTEN; stimulated by NF-B | Overexpression cell survival and proliferation | Stage |
|
